Obesity & Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Insulin Therapy
Combination therapy with Actos improves components of diabetic dyslipidemia
May 31st, 2004
Results of three studies show that the oral anti-diabetic agent Actos (pioglitazone HCl), in combination with a sulfonylurea, metformin or insulin, resulted in triglyceride decreases and high-density lipoprotein (HDL) cholesterol increases that demonstrated statistically significant improvements from baseline. These studies also showed that, in addition to increasing low-density lipoprotein (LDL) cholesterol particle size, Actos can significantly increase the size and buoyancy of HDL particles. The findings were presented at the 13th Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists (AACE) in Boston. "The...
Source: Obesity & Diabetes Week (2004-05-31)
|
